Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.

Antimicrobial Agents and Chemotherapy
Ernane SouzaManjunath P Pai

Abstract

In patients with renal impairment (n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

References

May 6, 2003·The Journal of Antimicrobial Chemotherapy·Gary French
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Michael E BrierGail L Jungbluth
Oct 9, 2003·Clinical Pharmacokinetics·Dennis J Stalker, Gail L Jungbluth
Sep 16, 2008·International Journal of Antimicrobial Agents·Kazuaki MatsumotoNorifumi Morikawa
Feb 1, 2011·Journal of Chemical Information and Modeling·Patrizia CrivoriAnna Maria Giusti
Nov 18, 2014·European Journal of Clinical Pharmacology·Lea S BlaserAlexandra E Rätz Bravo
Mar 17, 2016·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoMichael Neely
Dec 22, 2016·The Journal of Antimicrobial Chemotherapy·Abed Zahedi BialvaeiHossein Samadi Kafil
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Erica Yookyung Lee, Aisling R Caffrey
Feb 13, 2018·Journal of Basic and Clinical Physiology and Pharmacology·Ernane C de SouzaJorge W L Nascimento
May 22, 2019·Antimicrobial Agents and Chemotherapy·Ryan L CrassFederico Pea
Jul 2, 2019·Therapeutic Drug Monitoring·Sonia LuqueJason A Roberts
Oct 28, 2019·Therapeutic Drug Monitoring·Gauri G RaoUNKNOWN IATDMCT Antimicrobial Scientific Committee
Nov 16, 2019·Journal of Pharmaceutical and Biomedical Analysis·Ernane SouzaManjunath P Pai

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.